JPRN-UMIN000008189已完成未知
Feasibility study of carboplatin, paclitaxel and bevacizumab in advanced non-squamous non-small-cell lung cancer with idiopathic interstitial pneumonias - Feasibility study of carboplatin, paclitaxel and bevacizumab in advanced non-squamous non-small-cell lung cancer with idiopathic interstitial pneumonias
The Ministry of Health, Labour and Welfare of Japan awarded to the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on intractable diseases0 个研究点目标入组 27 人开始时间: 2012年6月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Acute or subacute idiopathic interstitial pneumonia 2.Being suspected or experienced acute exacerbation of idiopathic interstitial pneumonia. 3.Receiving immunosuppressants except for predonine 4.Having collagen diseases 5.Having central nervous system (CNS) metastases 6.History of gross hemoptysis (2.5ml or more) or severe hemosputum (reciving hemostatic drug) 7.Evidence of tumor invading large vessel, trachea or main bronchus on imaging 8.Patients who have received a radiation therapy in chest 9.Having an uncontrolled infection 10.Having a fever (more than 38 degrees (Celsius)) 11.Having severe complications 12.Having massive ascites, pleural effusion or pericardial effusion 13.Active concomitant malignancy without evidence of recurrence within 5 years 14.Having severe drug allegy 15.Evidence of gastrointestinal bleeding, intestinal obstruction and gastrointestinal ulceration 16.History or evidence of uncontrollable gastrointestinal ulceration or gastrointestinal perforation (within 1 year) 17.Having a tendency to bleed. Receiving anticoagulant drug (except Aspirin under 324mg/day). 18.Having a schedule of operations 19.Pulmonary tumor with the cavity (more than 1cm) 20.History of pregnancy or lactation, 21.History of myocardial infarction or cerebral infarction (within 1 year) 22.Haiving hypersensitivity to carboplatin, paclitaxel and bevacizumab, Cremophor E or alchol. 23.Using a home oxygen therapy 24.Decision of ineligibility by the attending physician
研究者
相似试验
已完成
不适用
A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancernresectable locally advanced non-small-cell lung cancerJPRN-UMIN000032376Department of Thoracic Oncology, Kansai Medical University Hospiital10
已完成
2 期
Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.JPRN-UMIN000006767Shizuoka Cancer Center32
招募中
2 期
Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and NeckJPRN-jRCTs031180358Tahara Makoto46
招募中
2 期
Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and NeckHead and Neck cancerJPRN-UMIN000014430IC-PCE study executive committee34
已完成
2 期
Neoadjuvant Therapy for Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian CancerNCT01146795Jason D. Wright32